The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Treatment of aggressive NHL in frail patients: cardiac comorbidities and advanced age
Pieternella Lugtenburg
• 20 Jun 2019
Pieternella Lugtenburg, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the treatment of aggressive non-Hodgkin lymphoma in frail patients, particularly due to cardiac comorbidities and advanced age. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
